“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Revolutionary ovarian cancer rapid test available Q4 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The company also raised Rs 270 crore investment from Temasek in 2019
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Subscribe To Our Newsletter & Stay Updated
